Abstract: Peptides synthesized to match the human ?1 (I) and ?2 (I) amino-telopeptide sequences of type I collagen degradation products in body fluids, preferably either Asp-GIu-Lys-Ser-Thr-Gly-Gly (SEQ ID NO:5) or Gln-Tyr-Asp-Gly-Lys-Gly-Val-Gly (SEQ ID NO:6). used as calibrators and antigens in immunoassays for detecting type I collagen degradation products in body fluids.

Abstract: Peptides synthesized to match C-telopeptide components of type III collagen degradation products in body fluids, selected from among EKAGGF (SEQ ID NO:39), IGGEKAGG (SEQ ID NO:40), IGGEKAGGF (SEQ ID NO:41), IAGIGGEKAGG (SEQ ID NO:42), IAGIGGEKAGGF (SEQ ID NO:43), and EKAGG (SEQ ID NO:44) are useful as immunogens and antigens in collagen resorption assays.

Abstract: A method for assaying bone resorption rates which consists of quantitating the concentration of peptide fragments derived from bone collagen, found in a body fluid is disclosed. The method includes immunometric assay, fluorometric assay and electrochemical titration. The structure of specific peptide fragments having 3-hydroxypyridinium cross-links found in urine of Paget's disease patients and procedures for making monoclonal antibodies is described.

Abstract: Peptides synthesized to match telopeptide components of type III collagen degradation products in body fluids, selected from among DVKSGVAVGG (SEQ ID NO:33), YDVKSGVAVGG (SEQ ID NO:34), SYDVKSGVAVGG (SEQ ID NO:35), DSYDVKSGVAVGG (SEQ ID NO:36), JYDSYDVKSGVAVGG (SEQ ID NO:37), EKAGGF (SEQ ID NO:39), IGGEKAGG (SEQ ID NO:40), IGGEKAGGF (SEQ ID NO:41), IAGIGGEKAGG (SEQ ID NO:42), and IAGIGGEKAGGF (SEQ ID NO:43) are useful as immunogens and antigens in collagen resorption assays.

Abstract: A method for assaying bone resorption rates which consists of quantitating the concentration of peptide fragments derived from bone collagen, found in a body fluid is disclosed. The method includes immunometric assay, fluorometric assay and electrochemical titration. The structure of specific peptide fragments having 3-hydroxypyridinium cross-links found in urine of Paget's disease patients and procedures for making monoclonal antibodies is described.

Abstract: Immunoassays for measuring type II collagen (cartilage) resorption in vivo employ either one or two antibodies. A first antibody binds to DEKAGGA (SEQ ID NO:21) but not to GGFDEKAGGAQLG (SEQ ID NO:27), where the K symbols refer to lysine or preferably to cross-linking 3-hydroxypyridinium residues. Measurement of analyte binding to the first antibody in serum provides an indication of unmineralized cartilage resorption in vivo. A second antibody binds to GGFDEKAGGAQLG but not to DEKAGGA. Measurement of analyte binding to the second antibody in serum provides an indication of mineralized cartilage resorption in vivo. An indication of total (unmineralized and mineralized) cartilage resorption in vivo is provided by either measurement of analyte binding to the first antibody in urine, or by measurement of the total analyte binding to the first and second antibodies in serum.

Abstract: Methods of determining collagen degradation in vivo, by quantitating the concentration of a peptide in a body fluid, the peptide being a C-terminal type II collagen telopeptide containing a hydroxylysyl pyridinoline cross-link or a type III collagen telopeptide containing a hydroxylysyl pyridinoline cross-link. Suitable methods include immunometric assays, fluorometric assays, and electrochemical titrations for quantitation. The structures of specific peptides having cross-links and kits for quantitating these peptides in a body fluid are described.

Abstract: Peptides synthesized to match N-telopeptide components of type III collagen degradation products in body fluids, selected from among DVKSGVAVGG (SEQ ID NO 33), YDVKSGVAVGG (SEQ ID NO 34), SYDVKSGVAVGG (SEQ ID NO 35), DSYDVKSGVAVGG (SEQ ID NO 36), JYDSYDVKSGVAVGG (SEQ ID NO 37), and KSGVAVGG (SEQ ID NO 45) are claimed. The peptides are useful as immunogens and antigens in collagen resorption assays.

Abstract: The claimed invention is peptides synthesized to match telopeptide components of type II collagen degradation products in synovial fluid and blood, selected from among LGPREKGPDP (SEQ ID NO 11), LGPREKGPDPLQ (SEQ ID NO 12), LGPREKGPDPLQY (SEQ ID NO 13), FAGLGPREKGPDP (SEQ ID NO 14), FAGLGPREKGPDPLQ (SEQ ID NO 15), FAGLGPREKGPDPLQY (SEQ ID NO 16), IDMSAFAGLGPREKGPDP (SEQ ID NO 17), IDMSAFAGLGPREKGPDPLQ (SEQ ID NO 18), IDMSAFAGLGPREKGPDPLQY (SEQ ID NO 19), and EKGPDPLQYMR (SEQ ID NO 20), which maybe useful as immunogens and antigens in cartilage resorption assays.

Abstract: The present invention is directed to ADAMTS3 and the corresponding protein ADAMTS-3 as well as variants, homologs, and equivalents, and their use in procollagen processing.

Abstract: An immunoassay kit for the quantification of degradation products of carboxy-terminal telopeptides of type I collagen in a human serum sample, including an antibody that is characterized by binding to at least one peptide derived from the carboxy-terminal telopeptide domain of type I collagen and isolatable from a urine sample of a patient with active Patet's disease.

Abstract: Immunoassays for measuring type II collagen (cartilage) resorption in vivo employ either one or two antibodies. A first antibody binds to DEKAGGA (SEQ ID NO:21) but not to GGFDEKAGGAQLG (SEQ ID NO:27), where the K symbols refer to lysine or preferably to cross-linking 3-hydroxypyridinium residues. Measurement of analyte binding to the first antibody in serum provides an indication of unmineralized cartilage resorption in vivo. A second antibody binds to GGFDEKAGGAQLG but not to DEKAGGA. Measurement of analyte binding to the second antibody in serum provides an indication of mineralized cartilage resorption in vivo. An indication of total (unmineralized and mineralized) cartilage resorption in vivo is provided by either measurement of analyte binding to the first antibody in urine, or by measurement of the total analyte binding to the first and second antibodies in serum.

Abstract: Immunoassays for measuring type II collagen (cartilage) resorption in vivo employ either one or two antibodies. A first antibody binds to DEKAGGA (SEQ ID NO:21) but not to GGFDEKAGGAQLG (SEQ ID NO:27), where the K symbols refer to lysine or preferably to cross-linking 3-hydroxypyridinium residues. Measurement of analyte binding to the first antibody in serum provides an indication of unmineralized cartilage resorption in vivo. A second antibody binds to GGFDEKAGGAQLG but not to DEKAGGA. Measurement of analyte binding to the second antibody in serum provides an indication of mineralized cartilage resorption in vivo. An indication of total (unmineralized and mineralized) cartilage resorption in vivo is provided by either measurement of analyte binding to the first antibody in urine, or by measurement of the total analyte binding to the first and second antibodies in serum.

Abstract: A method for assaying bone resorption rates which consists of quantitating the concentration of peptide fragments derived from bone collagen, found in a body fluid is disclosed. The method includes immunometric assay, fluorometric assay and electrochemical titration. The structure of specific peptide fragments having 3-hydroxypyridinium cross-links found in urine of Paget's disease patients and procedures for making monoclonal antibodies is described.

Abstract: Immunoassays for measuring type II collagen (cartilage) resorption in vivo employ either one or two antibodies. A first antibody binds to EKGPDP (SEQ ID NO:2) but not to EKGPDPLQ (SEQ ID NO:10), where the K symbols refer to lysine or preferably to cross-linking 3-hydroxypyridinium residues. Measurement of analyte binding to the first antibody in serum provides an indication of unmineralized cartilage resorption in vivo. A second antibody binds to EKGPDPLQ (SEQ ID NO:10) but not to EKGPDP (SEQ ID NO:2). Measurement of analyte binding to the second antibody in serum provides an indication of mineralized cartilage resorption in vivo. An indication of total (unmineralized and mineralized) cartilage resorption in vivo is provided by either measurement of analyte binding to the first antibody in urine, or by measurement of the total analyte binding to the first and second antibodies in serum.

Abstract: An enzyme linked immunosorbent assay (ELISA) kit for the quantification of degradation products of carboxy-terminal telopeptides of type I collagen in a human serum sample, including an antibody that is characterized by binding to at least one peptide derived from the carboxy-terminal telopeptide domain of type I collagen and isolatable from a urine sample of a patient with active Paget's disease.

Abstract: Immunoassay test kit for detecting analyte indicative of type II collagen resorption in vivo. including an immunological binding partner which binds to an amino-terminal or carboxy-terminal 3-hydroxypyridinium cross-linked telopeptide of type II collagen isolatable from a urine sample of a growing adolescent. Preferably the immunological binding partner does not cross-react more than 10% with the type I and type III collagen telopeptides of formulas III, VI, VIII, X, IX, and XI.

Abstract: Sandwich immunoassays for detecting analyte indicative of type II collagen resorption in vivo, by contacting a body fluid sample with a first antibody and a second antibody such that analyte present in the sample forms a first antibody-analyte-second antibody complex, and detecting the presence or amount of the first antibody-analyte-second antibody complex, wherein the first and second antibodies are capable of binding to a telopeptide having a sequence identical to that of a carboxy-terminal telopeptide produced in vivo upon degradation of type II collagen.

Abstract: Peptides synthesized to match the human .alpha.1(II) carboxy-telopeptide sequences of type II collagen degradation products in body fluids, preferably Glu-Lys-Gly-Pro-Asp-Pro (SEQ ID NO:6). Useful as calibrators and antigens in immunoassays for detecting type II collagen degradation products in body fluids.

Abstract: Sandwich immunoassays for detecting analyte indicative of type 1 collagen resorption in vivo, by contacting a body fluid sample with a first antibody and a second antibody such that analyte present in the sample forms a first antibody-analyte-second antibody complex, and detecting the presence or amount of the first antibody-analyte-second antibody complex, wherein the first and second antibodies are capable of binding to a telopeptide having a sequence identical to that of an amino-terminal or carboxy-terminal telopeptide produced in vivo upon degradation of type 1 collagen are claimed.